KalVista Pharmaceuticals (KALV) News Today → Revolutionizing the Green Energy Space and Building Shareholder Value Along the Way (From Small Cap Sniper) (Ad) Free KALV Stock Alerts $12.49 +0.49 (+4.08%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 4:46 AM | americanbankingnews.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Above 50-Day Moving Average of $11.90May 12 at 12:28 AM | morningstar.comKalVista Pharmaceuticals Inc KALVMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Masimo (MASI)May 7, 2024 | americanbankingnews.comHC Wainwright Trims KalVista Pharmaceuticals (NASDAQ:KALV) Target Price to $20.00May 4, 2024 | americanbankingnews.comNeedham & Company LLC Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)May 3, 2024 | marketbeat.comHC Wainwright Cuts KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $20.00HC Wainwright reduced their target price on shares of KalVista Pharmaceuticals from $24.00 to $20.00 and set a "buy" rating for the company in a research note on Friday.May 1, 2024 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 6.8%KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 6.8%May 1, 2024 | marketbeat.comKalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $35.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday.May 1, 2024 | finance.yahoo.comKalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal YearApril 22, 2024 | businesswire.comKalVista Pharmaceuticals Appoints William C. Fairey to Board of DirectorsApril 18, 2024 | marketbeat.comLeerink Partnrs Weighs in on KalVista Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:KALV)KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz expects that the specialty pharmaceutical compApril 17, 2024 | fool.comKalVista Pharmaceuticals (NASDAQ: KALV)April 15, 2024 | marketbeat.comVanguard Group Inc. Acquires 151,808 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Vanguard Group Inc. increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 9.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,732,489 shares of the specialty pharmaceutical company's stock after acquiring an additApril 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)April 11, 2024 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $35.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday.April 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)April 3, 2024 | businesswire.comKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading VolumeKalVista Pharmaceuticals (NASDAQ:KALV) Sees Strong Trading VolumeMarch 18, 2024 | finance.yahoo.comKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference AmericasMarch 18, 2024 | marketbeat.comResearch Analysts Offer Predictions for KalVista Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:KALV)KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a report released on Wednesday, March 13th. Cantor Fitzgerald analyst C. Duncan now anticipates that theMarch 16, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Up 50.8% in FebruaryKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw a large growth in short interest in February. As of February 29th, there was short interest totalling 4,510,000 shares, a growth of 50.8% from the February 14th total of 2,990,000 shares. Approximately 18.6% of the company's shares are sold short. Based on an average daily trading volume, of 762,300 shares, the days-to-cover ratio is currently 5.9 days.March 15, 2024 | marketbeat.comLeerink Partnrs Comments on KalVista Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:KALV)KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. Leerink Partnrs analyst J. Schwartz now forecasts that the sMarch 14, 2024 | marketbeat.comFY2024 EPS Estimates for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Lifted by HC WainwrightKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings estimates for shares of KalVista Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. HC Wainwright analyst A. Fein now forecasts that the specialty pharmacMarch 13, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Forecasted to Earn Q1 2025 Earnings of ($0.57) Per ShareKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for KalVista Pharmaceuticals in a note issued to investors on Tuesday, March 12th. HC Wainwright analyst A. Fein expects that the specialty pharmaceutical company wMarch 12, 2024 | markets.businessinsider.comBuy Rating on KalVista Pharmaceuticals Backed by Sebetralstat’s Breakthrough in HAE TreatmentMarch 12, 2024 | finance.yahoo.comKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for SebetralstatMarch 11, 2024 | markets.businessinsider.comBuy Rating Reinforced by Strategic CEO Appointment and Promising Drug Development at KalVista PharmaceuticalsMarch 11, 2024 | businesswire.comKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational UpdateMarch 8, 2024 | finanznachrichten.deKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasMarch 8, 2024 | businesswire.comKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasMarch 7, 2024 | marketwatch.comKalVista Pharmaceuticals Stock Falls After CEO ResignsMarch 7, 2024 | markets.businessinsider.comKalVista Stock Drops After Announcement Of Resignation Of CEO Andrew CrockettMarch 7, 2024 | marketwatch.comKalVista Pharmaceuticals Names Benjamin Palleiko Chief Executive, DirectorMarch 7, 2024 | businesswire.comKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive OfficerMarch 6, 2024 | businesswire.comKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma ConferenceMarch 4, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Sees Large Growth in Short InterestKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 2,990,000 shares, an increase of 21.1% from the January 31st total of 2,470,000 shares. Currently, 12.4% of the company's shares are sold short. Based on an average daily volume of 686,700 shares, the days-to-cover ratio is currently 4.4 days.March 1, 2024 | marketbeat.comMPM Bioimpact LLC Has $5.57 Million Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)MPM Bioimpact LLC trimmed its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 24.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 577,958 shares of the spFebruary 29, 2024 | marketbeat.comAnalysts Set Expectations for KalVista Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:KALV)KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of KalVista Pharmaceuticals in a research report issued on Monday, February 26th. Cantor Fitzgerald analyst C. Duncan now anticipates that the specialty phFebruary 28, 2024 | investing.comKalVista reports high efficacy for HAE drug in phase 3 trialFebruary 27, 2024 | finance.yahoo.comKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 27, 2024 | businesswire.comKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 26, 2024 | businesswire.comKalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 25, 2024 | msn.comKalVista Pharmaceuticals (KALV) Price Target Increased by 51.92% to 32.23February 20, 2024 | finance.yahoo.comKalVista Pharmaceuticals Awarded UK Innovation Passport for SebetralstatFebruary 20, 2024 | businesswire.comKalVista Pharmaceuticals Awarded UK Innovation Passport for SebetralstatFebruary 16, 2024 | finance.yahoo.comKalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 16, 2024 | marketbeat.comFY2024 EPS Estimates for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Cut by AnalystKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - HC Wainwright lowered their FY2024 EPS estimates for shares of KalVista Pharmaceuticals in a research note issued on Wednesday, February 14th. HC Wainwright analyst A. Fein now forecasts that the specialty pharmaceutical company will poFebruary 16, 2024 | businesswire.comKalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Revolutionizing the Green Energy Space and Building Shareholder Value Along the Way (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely! Learn how this American company is leading the lithium-ion revolution KALV Media Mentions By Week KALV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼0.470.57▲Average Medical News Sentiment KALV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼42▲KALV Articles Average Week Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TVTX News ALT News OCS News VERV News STTK News LRMR News ANL News CMPS News ABUS News ATXS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThis 1 Biotech Stock has been shocking the marketsHuge AlertsHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Report Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
